AbbVie Inc. (ABBV)
| Market Cap | 411.55B +32.6% |
| Revenue (ttm) | 61.16B +8.6% |
| Net Income | 4.23B -1.2% |
| EPS | 2.36 -1.3% |
| Shares Out | 1.77B |
| PE Ratio | 98.67 |
| Forward PE | 16.01 |
| Dividend | $6.92 (2.97%) |
| Ex-Dividend Date | Jan 16, 2026 |
| Volume | 7,336,664 |
| Open | 232.66 |
| Previous Close | 231.50 |
| Day's Range | 231.19 - 235.25 |
| 52-Week Range | 164.39 - 244.81 |
| Beta | 0.33 |
| Analysts | Buy |
| Price Target | 243.88 (+4.73%) |
| Earnings Date | Feb 4, 2026 |
About ABBV
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancer... [Read more]
Financial Performance
In 2025, AbbVie's revenue was $61.16 billion, an increase of 8.57% compared to the previous year's $56.33 billion. Earnings were $4.23 billion, a decrease of -0.28%.
Financial StatementsAnalyst Summary
According to 17 analysts, the average rating for ABBV stock is "Buy." The 12-month stock price target is $243.88, which is an increase of 4.73% from the latest price.
News
AbbVie: Dominating Immunology While Building Oncology Upside
None of the Big Pharma players has succeeded in challenging AbbVie's dominance in the immune-mediated inflammatory diseases market. In my view, this is directly related to the near-perfect complementa...
AbbVie Inc. (ABBV) Presents at Piper Sandler Virtual Novel Targets in Immunology Symposium Transcript
AbbVie Inc. (ABBV) Presents at Piper Sandler Virtual Novel Targets in Immunology Symposium Transcript
54 Stocks, 9 Megatrends: My Favorite Places To Be While Capital Is 'Forced'
My top-down strategy targets 'mission-critical' sectors where capital is forced by secular and cyclical tailwinds—data centers, energy, AI, defense, and infrastructure. AI-driven data center and energ...
AbbVie sues US health agency over Botox price controls
AbbVie sued the U.S. Department of Health and Human Services on Wednesday, challenging a decision by the Centers for Medicare & Medicaid Services to impose price controls for Botox.
Abbvie sues US health agency over Botox
Abbvie sued the U.S. Department of Health and Human Services on Wednesday, challenging a decision by the Centers for Medicare & Medicaid Services to select Botox for prescription drug price controls e...
Dividend Kings: No Ideal Buys In February's 57
Dividend Kings remain broadly overvalued, with only a handful approaching fair price despite elevated yields. Three Dividend Kings—Canadian Utilities, Fortis, and Hormel—currently meet the dogcatcher ...
AbbVie: The Market Is Getting It Wrong
AbbVie delivered a resilient Q4 with 10% YoY revenue growth and strong immunology performance, despite a post-earnings stock selloff. Their adjusted EPS grew 25% YoY, beating estimates, while operatin...
AbbVie: Skyrizi And Rinvoq Growth Isn't Everything, But It's A Lot
AbbVie has significantly outperformed prior immunology sales projections, with Skyrizi and Rinvoq now expected to reach $38 billion by 2030. ABBV's oncology and neuroscience pipelines have expanded vi...
AbbVie: Double-Digit Growth For Immunology Products Continues With HUMIRA Surprise
AbbVie Inc. retains a Strong Buy rating, driven by a positive earnings surprise in Q4 2025, notably due to HUMIRA outperformance. Despite ongoing HUMIRA declines, ABBV demonstrates robust growth in it...
AbbVie Q4 Earnings Review: I May Have Just Made A Huge Mistake
AbbVie Inc. has delivered strong long-term returns and maintains a >3% dividend yield, but recent Q4 earnings and guidance have tempered my near-term enthusiasm. ABBV's immunology and neuroscience div...
AbbVie's Immunology Fortress Can't Hide Cracks In Diversification (Downgrade)
AbbVie Inc. faces investor skepticism on growth durability beyond Immunology, despite strong SKYRIZI and RINVOQ performance offsetting HUMIRA's decline. ABBV's Q4 2025 saw 18% Immunology growth and 10...
AbbVie Inc. (ABBV) Q4 2025 Earnings Call Transcript
AbbVie Inc. (ABBV) Q4 2025 Earnings Call Transcript
AbbVie's Inflammation Drug Humira Slows, But Skyrizi, Rinvoq Drive Revenue Growth
AbbVie Inc. (NYSE: ABBV) reported fourth-quarter 2025 sales of $16.62 billion on Wednesday, beating the consensus of $16.42 billion.
AbbVie Revenue Rises on Immunology Growth
AbbVie posted higher fourth-quarter revenue on the back of growth from its immunology portfolio, led by arthritis and Crohn's disease drugs Skyrizi and Rinvoq.
AbbVie Earnings Beat Wall Street Expectations. The Stock Is Falling Anyway.
AbbVie posts better-than-expected earnings but revenue declines across certain business lines.
AbbVie forecasts 2026 profit above estimates on strong sales of newer immunology drugs
AbbVie forecast 2026 profit above Wall Street estimates on Wednesday after posting a fourth-quarter results beat, fueled by strong demand for newer immunology drugs Skyrizi and Rinvoq and a smaller-th...
AbbVie Reports Full-Year and Fourth-Quarter 2025 Financial Results
Reports Full-Year Diluted EPS of $2.36 on a GAAP Basis, a Decrease of 1.3 Percent; Adjusted Diluted EPS of $10.00, a Decrease of 1.2 Percent; These Results Include an Unfavorable Impact of $2.76 Per S...
Allergan Aesthetics Continues Its Mission of Empowering Women Through the Faces of Natrelle® Testimonial Program
The nationwide program invites eligible Natrelle® breast augmentation and reconstruction patients to share their personal experiences. Natrelle® champions women's voices to provide support at every st...
AbbVie Submits Regulatory Applications to FDA and EMA for Upadacitinib (RINVOQ®) in Adults and Adolescents With Vitiligo
Submissions are supported by data from the Phase 3 Viti-Up clinical studies demonstrating upadacitinib achieved the co-primary endpoints of at least a 50% improvement in total body re-pigmentation (T-...
Harbor Small Cap Growth Fund Q4 2025 Portfolio Performance
From a sector perspective, strength within Industrials and Information Technology offset relative weakness in Health Care. The October earnings report reinforced confidence in Comfort Systems' ability...
10 Highest Rated Dividend Kings For Generations Of Income
My top 10 Dividend Kings list prioritizes reliability, dividend safety, and attractive valuation for long-term, generational income. Selection criteria include payout ratios under 70%, strong dividend...
AbbVie Launches Love in Mind™ to Spotlight the Emotional Impact of Migraine on Romantic Relationships
~3 out of 4 respondents said migraine attacks have stood in the way of romantic relationships, according to new Harris Poll survey Wife, mother, country music star, and entrepreneur Jessie James Decke...
Allergan Aesthetics Unveils New Data Across Facial Injectables On-Market and Emerging Portfolio at IMCAS 2026 Showcasing Enduring Strength in Advancing Aesthetics Medicine
- N ine e-posters presenting comprehensive Allergan Aesthetics portfolio data spanning first-in-class botulinum neurotoxin serotype E (TrenibotulinumtoxinE, "TrenibotE"), onabotulinumtoxinA, hyaluron...
US Medicare names Eli Lilly, Pfizer and AbbVie drugs for next Medicare price talks
The U.S. Centers for Medicare & Medicaid Services on Tuesday named a new group of branded drugs from major pharmaceutical companies including Eli Lilly , Pfizer and AbbVie for the third cycle of the M...